Advertisement

Staging and Treatment of Non-Hodgkin’s Lymphomas

  • Charles H. Diggs
Part of the Developments in Oncology book series (DION, volume 2)

Abstract

The non-Hodgkin’s lymphomas are a somewhat heterogeneous group of diseases as can be seen from the previous article on their pathologic characteristics. Their clinical presentations may be similar to benign diseases, so before any treatment can be instituted for malignant lymphoma, two areas must be investigated. The first of these is biopsy of an area of clinical involvement to make the diagnosis, since few characteristics distinguish primary lymphoid malignancies from other benign disorders that cause lymphadenopathy. Secondly, the extent of disease (stage) must be adequately defined before appropriate therapy can be instituted.

Keywords

Complete Remission Malignant Lymphoma Vinca Alkaloid Single Agent Chemotherapy Histiocytic Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Freeman, C, JW Berg, and 53 Cutler, Occurrence and prognosis of extranodal lymphomas. Cancer 29: 252–260, 1972PubMedCrossRefGoogle Scholar
  2. 2.
    Bloomfield, CD, A Goldman, F Dick, et al, Multivariate analysis of prognostic factors in the non-Hodgkin’s malignant lymphomas. Cancer 33: 870–879, 1974PubMedCrossRefGoogle Scholar
  3. 3.
    Peters, MV, RS Bush, TC Brown, et al, The place of radiotherapy in the control of non-Hodgkin’s lymphomata. Br J Cancer 31 (Ií): 386–401, 1975CrossRefGoogle Scholar
  4. 4.
    Goffinet DR, R Warnke, NR Dunnick, et al, CLinical and surgical (laparotomy) evaluation of patients with non-Hodgkin’s lymphomas. Cancer Treat Rep 61: 981–992, 1977PubMedGoogle Scholar
  5. 5.
    Levi, JA, MJ O’Connell, WL Murphy, et al, Role of 67gallium citrate scanning in the management of non-Hodgkin’s lymphoma. Cancer 36: 1690 1741, 1975Google Scholar
  6. 6.
    Long, JC, MC Mihm, and R Qazi, Malignant lymphoma of the skin. Cancer 38: 1282–1296, 1976PubMedCrossRefGoogle Scholar
  7. 7.
    Reimer, RR, BA Chabner, RC Young, et al, Lymphoma presenting in bone. Ann Intern Med 87: 50–55, 1977PubMedGoogle Scholar
  8. 8.
    Woolley, PV, CK Osborne, JA Levi, et al, Extranodal presentation of non-Hodgkin’s lymphomas in the testis. Cancer 38: 1026–1035, 1976PubMedCrossRefGoogle Scholar
  9. 9.
    Fuks, Z and HS Kaplan, Recurrence rates following radiation therapy of nodular and diffuse malignant lymphomas. Radiology 108: 675–684, 1973PubMedGoogle Scholar
  10. 10.
    Hellman, S, JT Chaff ey, DS Rosenthal, et al, The place of radiation therapy in the treatment of non-Hodgkin’s lymphomas. Cancer 39: 843–851, 1977PubMedCrossRefGoogle Scholar
  11. 11.
    Reddy, S, VS Saxena, EV Pellettiere, et al, Early nodal and extra-nodal non-Hodgkin’s lymphomas. Cancer 40: 98–104, 1977PubMedCrossRefGoogle Scholar
  12. 12.
    Bush, RS, M Gospodarowicz, J Sturgeon, et al, Radiation therapy of localized non-Hodgkin’s lymphoma. Cancer Treat Rep 61: 1129–1136, 1977PubMedGoogle Scholar
  13. 13.
    Jones, SE, Z Fuks, HS Kaplan, et al, Non-Hodgkin’s lymphomas: V. Results of radiotherapy. Cancer 32: 682–691, 1973PubMedCrossRefGoogle Scholar
  14. 14.
    Cox, 3D, Central lymphatic irradiation to low dose for advanced nodular lymphoreticular tumors (non-Hodgkin’s lymphoma). Radiology 126: 767772, 1978Google Scholar
  15. 15.
    Glatstein, E, Z Fuks, DR Goffinet, et al, Non-Hodgkin’s lymphomas of stage III extent. Cancer 37: 2806–2812, 1976PubMedCrossRefGoogle Scholar
  16. 16.
    Lattuada, A, G Bonadonna, F Milani, et al, Adjuvant chemotherapy with CVP after radiotherapy (RT) in stage I-II non-Hodgkin’s lymphomas. In Adjuvant Therapy of Cancer, Salmon SE and SE Jones (eds). Amsterdam, Elsevier/North Holland Biomedical Press, 1977, p 537–544Google Scholar
  17. 17.
    Panahon, A, JH Kaufman, JA Grasso, et al, Randomized study of radiation therapy (RT) vs RT and chemotherapy (CT) on stage IA-IIIB non-Hodgkin’s lymphoma (NHL). Proc Am Soc Clin Oncol 18: 321, 1977Google Scholar
  18. 18.
    Chaff ey, JT, S Hellman, DS Rosenthal, et al, Total-body irradiation in the treatment of lymphocytic lymphoma. Cancer Treat Rep 61: 1149–1152, 1977Google Scholar
  19. 19.
    Qasim, MM, Total body irradiation in non-Hodgkin lymphoma. Strahlentherapie 149: 364–367, 1975PubMedGoogle Scholar
  20. 20.
    Johnson, RE, Total body irradiation (TBI) as primary therapy for advanced lymphosarcoma. Cancer 35: 242–246, 1975PubMedCrossRefGoogle Scholar
  21. 21.
    Brace, K, MJ O’Connell, V Vogel, et al, Total body radiation therapy for disseminated lymphosarcoma: results of a pilot study. Cancer Chemother Rep 58: 401–405, 1974PubMedGoogle Scholar
  22. 22.
    Garrett, MJ and S Das, A preliminary study in treatment of non-Hodgkin’s lymphoma by whole body irradiation. Clin Radiol 27: 409–414, 1976PubMedCrossRefGoogle Scholar
  23. 23.
    Young, RC, RE Johnson, GP Canellos, et al, Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination. Cancer Treat Rep 61: 1153–1159, 1977PubMedGoogle Scholar
  24. 24.
    Galton, DAG, LG Israels, JDN Nabarro, et al, Clinical trials of p-(DI-2chloroethylamino)-phenyl-butyric acid (CB 1348) in malignant lymphoma. Brit Med J 2: 1172–1176, 1955PubMedCrossRefGoogle Scholar
  25. 25.
    Carbone, PP and C Spurr, Management of patients with malignant lymphoma: A comparative study with cyclophosphamide and vinca alkaloids. Cancer Res 28: 811–822, 1968PubMedGoogle Scholar
  26. 26.
    Jones, SE, SA Rosenberg, HS Kaplan, et al, Non-Hodgkin’s lymphomas II: Single agent chemotherapy. Cancer 30: 31–38, 1972PubMedCrossRefGoogle Scholar
  27. 27.
    O’Connell, MJ, PH Wiernik and JC Sutherland, Highdose intermittent intravenous cyclophosphamide in non-Hodgkin’s lymphomas: longterm patient follow up. Oncology 33: 170–172, 1976PubMedCrossRefGoogle Scholar
  28. 28.
    Bagley CM, VT DeVita Jr, CW Berard, et al, Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Ann Intern Med 76: 227–234, 1972PubMedGoogle Scholar
  29. 29.
    Lenhard, RE Jr, RL Prentice, AH Owens Jr, et al, Combination chemotherapy of the malignant lymphomas. Cancer 38: 1052–1059, 1976PubMedCrossRefGoogle Scholar
  30. 30.
    Benjamin, RS, PH Wiernik, M3 O’Connell, et al, A comparison of cyclophosphamide, vincristine, and prednisone (COP) with nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP) in the treatment of nodular, poorly differentiated lymphocytic lymphoma. Cancer 38: 1896 1902, 1976Google Scholar
  31. 31.
    McKelvey, EM, JA Gottlieb, HE Wilson, et al, Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38: 1484–1493, 1976PubMedCrossRefGoogle Scholar
  32. 32.
    Stein, RS, EM Moran, RK Desser, et al, Combination chemotherapy of lymphomas other than Hodgkin’s disease. Ann Intern Med 81: 601–609, 1974PubMedGoogle Scholar
  33. 33.
    Durant, JR, RA Gams, AA Bartolucci, et al, BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin’s lymphoma. Cancer Treat Rep 61: 1085–1096, 1977PubMedGoogle Scholar
  34. 34.
    Rodriguez, V, F Cabanillas, MA Burgess, et al, Combination chemotherapy (“CHOP-Bleo”) in advanced (non-Hodgkin) malignant lymphoma. Blood 49: 325–333, 1977PubMedGoogle Scholar
  35. 35.
    Schein, PS, VT DeVita Jr, S Hubbard, et al, Bleomycin, Adriamycin, cyclophosphamide, vincristine and prednisone (BACOP) combination chemotherapy in the treatment of diffuse histiocytic lymphoma. Annals Intern Med 85: 417–422, 1976Google Scholar
  36. 36.
    Monfardini, S, G Tancini, M DeLena, et al, Cyclophosphamide, vincristine and prednisone (CVP) versus Adriamycin, bleomycin, and prednisone (ABP) in stage IV non-Hodgkin’s lymphomas. Med Ped Oncol 3: 67–74, 1977CrossRefGoogle Scholar
  37. 37.
    Lauria, F, M Baccarani, M Fiacchini, et al, Methotrexate, cyclophosphamide and vincristine (MEV regimen) for non-Hodgkin’s lymphoma. Europ J Cancer 11: 343–349, 1975CrossRefGoogle Scholar
  38. 38.
    Portlock, CS and SA Rosenberg, Chemotherapy of the non-Hodgkin’s lymphomas: the Stanford experience. Cancer Treat Rep 61: 1049–1055, 1977PubMedGoogle Scholar
  39. 39.
    Diggs, CH and PH Wiernik, Nodular lymphoma-complete remission prolongs survival. Blood 52 (Suppl 1): 246, 1978Google Scholar
  40. 40.
    Portlock CS and SA Rosenberg, No initial therapy for stage III and IV non-Hodgkin’s lymphomas of favorable histologic types. Ann Intern Med 90: 1013, 1979Google Scholar
  41. 41.
    Kennedy BJ, CD Bloomfield, DT Kiang, et al, Combination versus successive single agent chemotherapy in lymphocytic lymphoma. Cancer 41: 23–28, 1978PubMedCrossRefGoogle Scholar
  42. 42.
    Lister, TA, MH Cullen, MEJ Beard, et al, Comparison of combined and single agent chemotherapy in non-Hodgkin’s lymphoma of favourable histological type. Brit Med J 1: 533–537, 1978PubMedCrossRefGoogle Scholar
  43. 43.
    Ezdinli, EZ, W Costello, RE Lenhard Jr, et al, Survival of nodular versus diffuse pattern lymphocytic poorly differentiated lymphoma. Cancer 41: 1990–1996, 1978CrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers bv, The Hague 1980

Authors and Affiliations

  • Charles H. Diggs
    • 1
  1. 1.Baltimore Cancer Research Program of the Division of Cancer TreatmentNational Cancer Institute at the University of Maryland HospitalBaltimoreUSA

Personalised recommendations